Which stocks are moving after the closing bell on Tuesday?
By Mill Chart
Last update: Apr 23, 2024
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
After hours gainers
| Ticker | Change | Comment |
|---|---|---|
| CSSE | 56.2% | After the regular session, CHICKEN SOUP FOR THE SOUL EN (NASDAQ:CSSE) continues to impress in the after-hours session, with a 56.2% increase to $0.24. The stock is trading 56.71% lower than 6 months ago. |
| CLEU | 12.15% | CHINA LIBERAL EDUCATION HOLD's (NASDAQ:CLEU) stock price is advancing with 12.15% to a price of $1.2. In the last 3 months the share price dropped with 58.2%. |
| CDTX | 10.93% | After the regular session, CIDARA THERAPEUTICS INC (NASDAQ:CDTX) continues to impress in the after-hours session, with a 10.93% increase to $0.57. Shareholders saw the stock price going 31.34% lower in the past month. |
| TSLA | 7.34% | Impressive after-hours gains for TESLA INC (NASDAQ:TSLA) as its stock price advanced 7.34% to $155.3 during Tuesday's after-hours session. TESLA INC released earnings Yesterday. Yesterday the company had a press release: Tesla Stock Analysis: Insights and Future Projections. |
| WFRD | 6.7% | WEATHERFORD INTERNATIONAL PL's (NASDAQ:WFRD) shares rose 6.7% to $126.0 during Tuesday's after hours session. WEATHERFORD INTERNATIONAL PL released earnings Yesterday. The stock is trading 26.45% higher than 6 months ago. |
| BQ | 6.32% | In the after-hours session on Tuesday, BOQII HOLDING LTD (NYSEARCA:BQ) experienced a notable 6.32% increase, driving its shares to $0.27. Shareholders saw the stock price going 31.23% lower in the past 3 months. |
| VLCN | 6.01% | VOLCON INC's (NASDAQ:VLCN) stock price increased by 6.01% to $0.31. The positive market sentiment seen in today's regular session, where NASDAQ:VLCN closed with a 26.38% gain, carries over into the after-hours session. |
| TXN | 5.39% | TEXAS INSTRUMENTS INC's (NASDAQ:TXN) shares rose 5.39% to $174.39. TEXAS INSTRUMENTS INC released earnings Yesterday. |
| ABVC | 5.19% | Positive after-hours movement for ABVC BIOPHARMA INC (NASDAQ:ABVC) as its shares recorded a 5.19% increase, reaching $1.42 during Tuesday's after-hours session. This is a continuation of today's gain of 29.81%. |
| ADVM | 5.0% | Notable gains for ADVERUM BIOTECHNOLOGIES INC (NASDAQ:ADVM) in the after-hours session, with a 5.0% rise to $11.55 during Tuesday. Shareholders saw the stock price going 26.42% lower in the past month. |
To see the full list of after hours gainers you can use our after hours gainers page.
Today's after hours losers
| Ticker | Change | Comment |
|---|---|---|
| FRES | -17.23% | Today's after-hours session sees a continuation of the 20.82% decrease earlier in the day for NASDAQ:FRES. Price movements remain volatile as NASDAQ:FRES gives back 20.82% of its earlier gains in the after-hours session. A press release (Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq) was released two days ago. |
| KPRX | -13.79% | Following a 19.59% loss in the regular session, NASDAQ:KPRX exhibits further decline during today's after-hours session. Despite a strong 19.59% gain earlier today, NASDAQ:KPRX is experiencing a reversal in after-hours trading, with prices declining by 13.79%. |
| CLDI | -10.24% | After today's %ABSPERF% drop, NYSEARCA:CLDI shows further decline during today's after-hours session with a 10.24% decrease. Yesterday the company had a press release: Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24. |
| EQX | -8.04% | Price volatility persists as NYSEARCA:EQX closed the regular session with a %ABSPERF% loss, and the downward trend continues in the after-hours session. A press release (Equinox Gold Consolidates Ownership of the Greenstone Gold Mine, Arranges Term Loan and Bought Deal Equity Financing) was released earlier today. |
| TLSA | -7.95% | TIZIANA LIFE SCIENCES LTD's (NASDAQ:TLSA) shares experienced a 7.95% decrease to $0.71 in the after-hours session. yesterday the company released their earnings. A press release (Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program) was released yesterday. |
| NUWE | -6.67% | NUWELLIS INC's (NASDAQ:NUWE) shares fell 6.67% to $0.28 during Tuesday's after hours session. It appears that the downward trend persists as NASDAQ:NUWE also experienced a -10.18% decline during the regular session. |
| ASLN | -6.38% | ASLAN PHARMACEUTICALS LT-ADR's (NASDAQ:ASLN) stock price saw a decrease of 6.38% to $0.44 during Tuesday's after-hours session. Two days ago the company had a press release: ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients. |
| SING | -5.91% | Price volatility persists as NYSEARCA:SING closed the regular session with a 18.16% loss, and the downward trend continues in the after-hours session. After registering a 18.16% gain earlier today, NYSEARCA:SING is experiencing a 5.91% decline in today's after-hours session. |
| AULT | -5.68% | Today's after-hours session sees a continuation of the %ABSPERF% decrease earlier in the day for NYSEARCA:AULT. Shareholders saw the stock price going 50.52% lower in the past 3 months. |
| SNGX | -5.0% | SOLIGENIX INC's (NASDAQ:SNGX) shares experienced a 5.0% decrease to $0.38 in the after-hours session. The stock is trading 35.48% lower than a month ago. |
To see the full list of after hours losers you can use our after hours losers page.
ABVC BIOPHARMA INC
NASDAQ:ABVC (5/6/2024, 7:00:00 PM)
After market: 1.09 +0.01 (+0.93%)1.08
0 (0%)
ABVC News
13 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) (
19 days ago - NewMediaWireAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
19 days ago - TheNewswire.comAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareFREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
20 days ago - NewMediaWireABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
a month ago - TheNewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MFREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.
a month ago - NewMediaWireABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (
a month ago - TheNewswire.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MFREMONT, CA - (NewMediaWire) - March 26, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
a month ago - NewMediaWireABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) (
2 months ago - TheNewswire.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsFREMONT, CA - (NewMediaWire) - March 21, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl BioPharma Inc. (AIBL), entered into an Agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share. The property is valued at approximately $7.6 million based on a third-party valuation.
